Faeth Therapeutics
FTH
34 hedge funds and large institutions have $22.6M invested in Faeth Therapeutics in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 14 increasing their positions, 13 reducing their positions, and 9 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 13
0.14% less ownership
Funds ownership: 0.52% → 0.38% (-0.14%)
15% less funds holding
Funds holding: 40 → 34 (-6)
51% less capital invested
Capital invested by funds: $45.7M → $22.6M (-$23.1M)
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.25M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$779K |
| 3 |
FG
Formula Growth
Montreal,
Quebec, Canada
|
+$540K |
| 4 |
State Street
Boston,
Massachusetts
|
+$509K |
| 5 |
AA
ALPS Advisors
Denver,
Colorado
|
+$497K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$5.45M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$5.05M |
| 3 |
AWG
Alpha Wave Global
New York
|
-$3.1M |
| 4 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$1.05M |
| 5 |
PVI
Pura Vida Investments
New York
|
-$553K |
FTH Hedge Fund Activity: Q2 2021 in Review
34 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q2 2021, worth a combined $22.6M — down 51% from $45.7M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of FTH and 3 opened new positions — a net loss of 6 holders — while 13 trimmed existing stakes and 14 added.
The largest buyer was Morgan Stanley, adding an estimated $1.25M. The largest seller was Deerfield Management, exiting entirely with an estimated $5.45M sold.
- 34 institutional investors held Faeth Therapeutics (FTH) as of Q2 2021, down from 40 in Q1 2021.
- Funds reported $22.6M of Faeth Therapeutics stock for Q2 2021, down 51% quarter-over-quarter.
- 3 funds opened new Faeth Therapeutics positions in Q2 2021 and 9 closed out, a net change of -6 holders.
- The largest Faeth Therapeutics buyer in Q2 2021 was Morgan Stanley, an estimated $1.25M added.
- The largest Faeth Therapeutics seller in Q2 2021 was Deerfield Management, an estimated $5.45M sold.
Based on aggregated 13F filings for Q2 2021.